Use of monitoring approaches to verify the predictive accuracy of the modeling of particle-bound solid inputs to surface waters

For particle-bound substances such as phosphorus, erosion is an important input pathway to surface waters. Therefore, knowledge of soil erosion by water and sediment inputs to water bodies at high spatial resolution is essential to derive mitigation measures at the regional scale. Models are used to calculate soil erosion and associated sediment inputs to estimate the resulting loads. However, validation of these models is often not sufficiently possible. In this study, sediment input was modeled on a 10 × 10 m grid for a subcatchment of the Kraichbach river in Baden-Wuerttemberg (Germany). In parallel, large-volume samplers (LVS) were operated at the catchment outlet, which allowed a plausibility check of the modeled sediment inputs. The LVS produced long-term composite samples (2 to 4 weeks) over a period of 4 years. The comparison shows a very good agreement between the modeled and measured sediment loads. In addition, the monitoring concept of the LVS offers the possibility to identify the sources of the sediment inputs to the water body. In the case of the Kraichbach river, it was found that around 67% of the annual sediment load in the water body is contributed by rainfall events and up to 33% represents dry-weather load. This study shows that the modeling approaches for calculating the sediment input provide good results for the test area Kraichbach and the transfer for a German wide modeling will produce plausible values

Ergebniskopplung KliWES - STOFFBILANZ in Sachsen: Analyse von Einflüssen des Klimawandels auf die Nährstoffeinträge in sächsische Gewässer auf Basis einer Ergebniskopplung der Projekte KliWES und STOFFBILANZ

Zur Abschätzung der Wirkungen von Klimaveränderungen auf den Nährstoffhaushalt in Gewässern wurden die Ergebnisse aus den Modellansätzen der Projekte »KliWES« und »Nährstoffatlas Sachsen« gekoppelt. Szenarienrechnungen bis 2100 zeigen, dass Nährstoffkonzentrationen in Gewässern infolge abnehmender Sickerwasser- und Durchflussmengen ohne Bewirtschaftungsanpassung tendenziell zunehmen würden. Die Veröffentlichung richtet sich an Verwaltungen, Planungsbüros, Verbände und Forschungseinrichtungen im Aufgabenbereich von Landwirtschaft und Gewässerschutz im Klimawandel

KliWES 2.0 – Klimawandel und Wasserhaushalt: Methodikoptimierung der Wasserhaushaltsmodellierung, Fortschreibung von Modelleingangsdaten, sachsenweite Wasserhaushaltsmodellierung für Ist-Zustand und Szenarien sowie Weiterentwicklung der KliWES-Internetanwendung im Wasserhaushaltsportal Sachsen

Die Schriftenreihe informiert über die Fortschreibung des Projektes „Klimawandel und Wasserhaushalt in Sachsen“ (KlIWES-2.0) mit einem weiterentwickelten ARCEGMO- Modell- Konzept. Zunächst erfolgte eine Neuberechnung des IST- Wasserhaushaltes bis 2015. Ergänzend wurden mit acht ausgewählten WEREX-VI- Klima- Realisierungen künftige Wasserhaushalts- Entwicklungen (bis 2100) modelliert. Die Ergebnisse zeigen überwiegend ein weiter abnehmende Abfluss- Dargebots- Entwicklung in den Gewässereinzugsgebieten. Über das neue Anwendungs- Tool „KliWES-2.0“ sind die Ergebnisse im „Wasserhaushaltsportal Sachsen“ für einen breiten Nutzerkreis auch webbasiert verfügbar. Redaktionsschluss: 10.06.202

The labor market effects of technology shocks

We analyze the effects of neutral and investment-specific technology shocks on hours worked and unemployment. We characterize the response of unemployment in terms of job separation and job finding rates. We find that job separation rates mainly account for the impact response of unemployment while job finding rates for movements along its adjustment path. Neutral shocks increase unemployment and explain a substantial portion of unemployment and output volatilityinvestment-specific shocks expand employment and hours worked and mostly contribute to hours worked volatility. We show that this evidence is consistent with the view that neutral technological progress prompts Schumpeterian creative destruction, while investment specific technological progress has standard neoclassical feature

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe